Praxis Precision Medicines (PRAX)

• Market cap: $681M
• 1 day: 13.28%
• 5 days: 20.16%
• 1 month: -13.20%
• 3 months: -52.10%
• 6 months: -54.90%
• Year to date: -57.51%
• 1 year: -33.46%
• 5 years: -91.90%
• 10 years: -91.90%
• Sector: Healthcare
• Industry: Biotechnology

About: Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.

Employees: 82

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

290% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 10

155% more call options, than puts

Call options by funds: $74.7M | Put options by funds: $29.3M

53% more capital invested

Capital invested by funds: $1.09B [Q3] → $1.67B (+$581M) [Q4]

40% more funds holding in top 10

Funds holding in top 10: 5 [Q3] → 7 (+2) [Q4]

22% more funds holding

Funds holding: 133 [Q3] → 162 (+29) [Q4]

10.31% more ownership

Funds ownership: 106.21% [Q3] → 116.53% (+10.31%) [Q4]

6% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 52

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $73 116% upside
• Avg. target: $92 172% upside
• High target: $111 228% upside

5 analyst ratings

• positive: 5 100%
• neutral: 0 0%
• negative: 0 0%

Needham Ami Fadia 13% 1-year accuracy 22 / 164 met price target	152% upside $85	Buy Reiterated	8 Apr 2025
Truist Securities Joon Lee 41% 1-year accuracy 17 / 41 met price target	152% upside $85	Buy Maintained	3 Mar 2025
Baird Joel Beatty 21% 1-year accuracy 8 / 38 met price target	116% upside $73	Outperform Maintained	3 Mar 2025
HC Wainwright & Co. Douglas Tsao 17% 1-year accuracy 29 / 171 met price target	211% upside $105	Buy Maintained	3 Mar 2025
Deutsche Bank David Hoang 12% 1-year accuracy 2 / 17 met price target	229% upside $111	Buy Initiated	11 Feb 2025